中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 39 Issue 2
Feb.  2023
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(2): 345-351

Effect of traditional Chinese medicine on portal vein thrombosis in patients with liver cirrhosis and its medication characteristics

DOI: 10.3969/j.issn.1001-5256.2023.02.014
  • 1.

    Second Department of Hepatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Institute of Liver Diseases, Shanghai Institute of Traditional Chinese Medicine, Shanghai 201203, China

  • 2.

    Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai 201203, China

  • 3.

    Key Laboratory of Liver and Kidney Diseases, Ministry of Education, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Research funding:

National Natural Science Foundation of China (81603467);

Three-year Action Plan for Promoting Clinical Skills and Clinical Innovation Capability of Municipal Hospitals in Shanghai· Clinical Skill Improvement Project for Major Diseases (16CR1026B)

More Information
  • Corresponding author: LYU Jing, ljliver@163.com (ORCID: 0000-0002-7577-0419); LIU Chenghai, chenghailiu@hotmail.com (ORCID: 0000-0002-1696-6008)
  • Received Date: 2022-09-15
  • Accepted Date: 2022-10-19
  • Published Date: 2023-02-20
    Abstract
  •   Objective  To investigate the therapeutic effect of traditional Chinese medicine (TCM) on portal vein thrombosis (PVT) in patients with liver cirrhosis and its medication characteristics.  Methods  A retrospective analysis was performed for 89 patients with liver cirrhosis and PVT who were hospitalized and treated in Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, and according to whether TCM treatment was applied in combination, they were divided into TCM group with 59 patients and control group with 30 patients. Related data were collected for the two groups, including demographic data, laboratory examination, radiological examination, gastroscopy, history of surgery, portal hypertension-related complications, medication, and follow-up data. The independent samples t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U rank sum test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test or the Fisher's exact test was used for comparison of categorical data between two groups. An ordinal polytomous Logistic regression analysis was used for multivariate analysis. TCM Inheritance Computing Platform (V3.0) was used to perform a drug effect cluster analysis of TCM prescriptions.  Results  The multivariate logistic regression analysis showed that esophageal and gastric varices (odds ratio [OR]=3.144, 95% confidence interval [CI]: 1.221-8.094), PVT involving the portal vein (PV) and the superior mesenteric vein (SMV) (OR=51.667, 95%CI: 3.536-754.859), PVT involving PV+spleen vein (SV)+SMV (OR=13.271, 95% CI: 2.290-76.928), cavernous transformation of the portal vein (OR=11.896, 95%CI: 1.172-120.696), and TCM intervention (OR=0.348, 95%CI: 0.129-0.938) were influencing factors for the outcome of PVT in liver cirrhosis. Follow-up results showed that compared with the control group, the TCM group had a significantly lower progression rate (16.95% vs 56.67%, P < 0.001) and a significantly lower incidence rate of variceal rupture and bleeding (8.47% vs 33.33%, P < 0.001). Effective TCM drugs with a relatively high frequency of use included deficiency-tonifying drugs (359 times, 34.6%), blood-activating and stasis-resolving drugs (202 times, 19.5%), and diuresis-inducing and dampness-draining drugs (180 times, 17.3%); the TCM drugs with a relatively high frequency of use included Astragalus membranaceus (57 times, 8.7%), Angelica sinensis (50 times, 7.6%), and leech (48 times, 7.3%); TCM drug combinations with a relatively high frequency of use included Astragalus membranaceus+Angelica sinensis, Astragalus membranaceus+leech, Angelica sinensis+leech, and Astragalus membranaceus+Angelica sinensis+leech.  Conclusion  Qi-tonifying, blood-activating, and stasis-breaking drugs, such as Astragalus membranaceus, Angelica sinensis, and leech, can promote the stabilization or recanalization of PVT in liver cirrhosis and reduce the incidence rate of bleeding events due to portal hypertension.

     

    • FullText(HTML)
    • References(15)
  • [1]
    SENZOLO M, GARCIA-TSAO G, GARCÍA-PAGÁN JC. Current knowledge and management of portal vein thrombosis in cirrhosis[J]. J Hepatol, 2021, 75(2): 442-453. DOI: 10.1016/j.jhep.2021.04.029.
    [2]
    STINE JG, SHAH PM, CORNELLA SL, et al. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis[J]. World J Hepatol, 2015, 7(27): 2774-2780. DOI: 10.4254/wjh.v7.i27.2774.
    [3]
    QI X, SU C, REN W, et al. Association between portal vein thrombosis and risk of bleeding in liver cirrhosis: A systematic review of the literature[J]. Clin Res Hepatol Gastroenterol, 2015, 39(6): 683-691. DOI: 10.1016/j.clinre.2015.02.012.
    [4]
    INTAGLIATA NM, CALDWELL SH, TRIPODI A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis[J]. Gastroenterology, 2019, 156(6): 1582-1599. e1. DOI: 10.1053/j.gastro.2019.01.265.
    [5]
    MANCUSO A. Controversies in the management of portal vein thrombosis in liver cirrhosis[J]. J Clin Med, 2020, 9(12): 3916. DOI: 10.3390/jcm9123916.
    [6]
    LYU J, DONG SS, GU HT, et al. TCM syndrome characteristics of portal vein thrombosis in patients with liver cirrhosis and related risk factors[J]. J Clin Hepatol, 2019, 35(10): 2210-2213. DOI: 10.3969/j.issn.1001-5256.2019.10.016.

    吕靖, 董思思, 顾宏图, 等. 肝硬化并发门静脉血栓的危险因素及中医证候特点[J]. 临床肝胆病杂志, 2019, 35(10): 2210-2213. DOI: 10.3969/j.issn.1001-5256.2019.10.016.
    [7]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [8]
    Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai)[J]. J Clin Hepatol, 2020, 36(12): 2667-2674. DOI: 10.3969/j.issn.1001-5256.2020.12.007.

    中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年, 上海)[J]. 临床肝胆病杂志, 2020, 36(12): 2667-2674. DOI: 10.3969/j.issn.1001-5256.2020.12.007.
    [9]
    Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China[M]. Beijing: China Medical Science Press, 2015.

    国家药典委员会. 中国药典[M]. 北京: 中国医药科技出版社, 2015.
    [10]
    NERY F, CHEVRET S, CONDAT B, et al. Causes and consequences of portal vein thrombosis in 1, 243 patients with cirrhosis: results of a longitudinal study[J]. Hepatology, 2015, 61(2): 660-667. DOI: 10.1002/hep.27546.
    [11]
    AHMED Z, SINGAL AK, KAMATH PS. Anticoagulants and their monitoring[J]. Clin Liver Dis (Hoboken), 2020, 16(4): 146-148. DOI: 10.1002/cld.946.
    [12]
    GE L, ZHOU L. Effect of Huangqi Zezhu Danshen decoction and enoxaparin injection on liver cirrhosis complicated with portal vein thrombosis and its influence on coagulation function[J]. Chin J Thromb Hemost, 2021, 27(5): 742-743, 746. DOI: 10.3969/j.issn.1009-6213.2021.05.008.

    葛莉, 周蕾. 黄芪莪术丹参汤与依诺肝素注射液治疗肝硬化合并门静脉血栓形成的疗效及对凝血功能的影响[J]. 血栓与止血学, 2021, 27(5): 742-743, 746. DOI: 10.3969/j.issn.1009-6213.2021.05.008.
    [13]
    LI SX, XIONG JH, CAO JB. One case report of Anluo Huaxian pill in treatment of portal vein thrombosis of liver cirrhosis[J]. Beijing Med J, 2015, 37(3): 303-304. https://www.cnki.com.cn/Article/CJFDTOTAL-BJYX201503044.htm

    李绍祥, 熊锦华, 曹建彪. 安络化纤丸治疗肝硬化门静脉血栓1例报告[J]. 北京医学, 2015, 37(3): 303-304. https://www.cnki.com.cn/Article/CJFDTOTAL-BJYX201503044.htm
    [14]
    RODRIGUEZ-CASTRO KI, VITALE A, FADIN M, et al. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis[J]. Eur J Gastroenterol Hepatol, 2019, 31(1): 34-42. DOI: 10.1097/MEG.0000000000001237.
    [15]
    LV Y, BAI W, LI K, et al. Anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis: A prospective observational study[J]. Am J Gastroenterol, 2021, 116(7): 1447-1464. DOI: 10.14309/ajg.0000000000001194.
    • Relative Articles

  • Relative Articles

    [1]Xin SHI, Chongxiao LIANG, Bei ZHANG, Jiping WANG. Value of internal stratification analysis of abdominal wall muscles in predicting complications after orthotopic liver transplantation[J]. Journal of Clinical Hepatology, 2025, 41(2): 314-321. doi: 10.12449/JCH250218
    [2]Mingqiang ZHU, Dashuai YANG, Junpeng PEI, Xiangyun XIONG, Yang SU, Youming DING. Analysis of influencing factors on biliary complications after orthotopic liver transplantation[J]. Journal of Clinical Hepatology, 2023, 39(7): 1627-1632. doi: 10.3969/j.issn.1001-5256.2023.07.017
    [3]Xing DAI, Ben GAO, Xinxin ZHANG, Yanyan SUN, Wentao JIANG, Jiang LI. Establishment and validation of a risk prediction model for early-stage complications after liver transplantation[J]. Journal of Clinical Hepatology, 2022, 38(2): 402-408. doi: 10.3969/j.issn.1001-5256.2022.02.027
    [4]Rongjuan SUN, Jianghua ZHAN. Research advances in the diagnostic methods for biliary atresia[J]. Journal of Clinical Hepatology, 2022, 38(7): 1681-1685. doi: 10.3969/j.issn.1001-5256.2022.07.043
    [5]Nengli WANG, Xinbao XIE. Liver transplantation for pediatric acute liver failure[J]. Journal of Clinical Hepatology, 2022, 38(2): 278-281. doi: 10.3969/j.issn.1001-5256.2022.02.006
    [6]Bo HE, Xin WANG, Feng WANG, Yandong SUN, Qingguo XU, Ge GUAN, Yunjin ZANG. Influence of arterial variation and reconstruction of the donor hepatic artery in liver transplantation on early postoperative arterial complications[J]. Journal of Clinical Hepatology, 2021, 37(8): 1901-1904. doi: 10.3969/j.issn.1001-5256.2021.08.030
    [7]Perioperative Management Group, Chinese Society of Organ Transplantation, Chinese Medical Association. Expert consensus on perioperative vascular complications for liver transplantation(2021)[J]. Journal of Clinical Hepatology, 2021, 37(9): 2054-2057. doi: 10.3969/j.issn.1001-5256.2021.09.010
    [8]Chen WeiTing, Li ShuangJie. Clinical value of transient elastography,aspartate aminotransferase-to-platelet ratio index,and fibrosis-4 in the diagnosis of liver fibrosis in children with biliary atresia[J]. Journal of Clinical Hepatology, 2020, 36(3): 546-550. doi: 10.3969/j.issn.1001-5256.2020.03.015
    [9]Wang Kai, Gao Wei. Research advances in immune tolerance in children receiving liver transplantation[J]. Journal of Clinical Hepatology, 2019, 35(11): 2402-2407. doi: 10.3969/j.issn.1001-5256.2019.11.005
    [10]Liu YiHe, Zheng Hong, Shen ZhongYang. Tasks and strategies for the prevention and treatment of middle-and long-term complications after liver transplantation[J]. Journal of Clinical Hepatology, 2019, 35(11): 2386-2390. doi: 10.3969/j.issn.1001-5256.2019.11.002
    [11]Lu YeFeng, Xia Qiang, Qiu BiJun, Feng MingXuan, Wan Ping. An analysis of related issues in long-term survival in children after liver transplantation[J]. Journal of Clinical Hepatology, 2019, 35(11): 2396-2401. doi: 10.3969/j.issn.1001-5256.2019.11.004
    [12]Section of Hepatobiliary Surgery, Branch of Pediatric Surgery, Chinese Medical Association, Section of Pediatric Hepatic Transplantation, Branch of Organ Transplantation, Chinese Medical Doctor Association. Guidelines for diagnosing & treating biliary atresia (2018 Edition)[J]. Journal of Clinical Hepatology, 2019, 35(11): 2435-2440. doi: 10.3969/j.issn.1001-5256.2019.11.009
    [13]Xu Hui, Li Bing. Research advances in endoscopic treatment of biliary complications after liver transplantation[J]. Journal of Clinical Hepatology, 2018, 34(10): 2245-2250. doi: 10.3969/j.issn.1001-5256.2018.10.041
    [14]Jie EnBo, Xuan FengHui, Sun XiaoDong, Sun DaWei, Lu: GuoYue. An analysis of risk factors for early complications after liver transplantation[J]. Journal of Clinical Hepatology, 2018, 34(6): 1282-1288. doi: 10.3969/j.issn.1001-5256.2018.06.030
    [15]Wang MingYue, Lu ZhiYan. Imaging evaluation of complications after liver transplantation[J]. Journal of Clinical Hepatology, 2016, 32(12): 2295-2299. doi: 10.3969/j.issn.1001-5256.2016.12.013
    [16]Lu: GuoYue. Risk factors for biliary complications after liver transplantation from donation after cardiac death[J]. Journal of Clinical Hepatology, 2015, 31(12): 2027-2030. doi: 10.3969/j.issn.1001-5256.2015.12.009
    [17]Guo Jing, Xu LingFen, Sun Mei. Differential diagnosis of biliary atresia and intrahepatic cholestasis in children[J]. Journal of Clinical Hepatology, 2015, 31(8): 1252-1256. doi: 10.3969/j.issn.1001-5256.2015.08.017
    [18]Li JiangBin, Du XiLin, Dong Rui, Yin JiKai, Lu JianGuo. Incidence and prevention of liver transplantation- related cardiovascular complications[J]. Journal of Clinical Hepatology, 2014, 30(1): 75-77. doi: 10.3969/j.issn.1001-5256.2014.01.022
    [19]Hua XiangWei, Xia Qiang, Zhang JianJun, Li QiGen, Xu Ning, Chen XiaoSong, Zhang Ming, Xue Feng, Han LongZhi, Wang Xin, Xia Lei, Luo Yi, Shen CongHuan, Xing TianYu, Xi ZhiFeng. Prognos is of living donor liver transplantation performed during different periods in infants with biliary atresia: a single- center experience with 101 cases[J]. Journal of Clinical Hepatology, 2014, 30(1): 18-22. doi: 10.3969/j.issn.1001-5256.2014.01.006
    [20]Shen ZhongYang. Diagnosis and management of ischemic-type biliary lesion after liver transplantation[J]. Journal of Clinical Hepatology, 2010, 26(4): 368-370.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(6)

    1. 费蕾蕾，万素莲，李炳，周玥，袁敏，黄萍，孟红艳，张媛媛，苏梦瑶，裴一善. 3D腹腔镜肝门空肠吻合术治疗小儿胆道闭锁的护理配合. 长春中医药大学学报. 2021(04): 888-891 .
    2. 刘炎忠，柏宏伟，钱叶勇，石炳毅，常京元，李超，李钢，解俊杰，余飞. DCD时代肾移植术后耐碳青霉烯类肺炎克雷伯菌感染的治疗经验总结. 器官移植. 2020(01): 76-81 .
    3. 李彩妃，胡爱玲，周青. 1例肝移植术后胆肠吻合口瘘及伤口愈合不良患儿的护理. 护理学杂志. 2020(09): 40-41 .
    4. 刘坚，董汉华. 肝移植围手术期护理质量指标研究进展. 现代医学与健康研究电子杂志. 2020(12): 98-101 .
    5. 聂静雨，周春莲，宋丽红，陈惠清. 先天性胆道闭锁患儿肝移植术后医院感染情况及其影响因素分析. 北京医学. 2020(10): 934-937 .
    6. 杨红梅，罗毅，马敬香，叶丽彦. 胆道闭锁患儿葛西术后行肝移植术护理. 齐鲁护理杂志. 2018(08): 110-112 .

    Other cited types(1)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 2.9 %FULLTEXT: 2.9 %META: 94.1 %META: 94.1 %PDF: 2.9 %PDF: 2.9 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 6.4 %其他: 6.4 %其他: 0.9 %其他: 0.9 %Bengaluru: 0.2 %Bengaluru: 0.2 %Central District: 0.1 %Central District: 0.1 %China: 0.5 %China: 0.5 %India: 0.2 %India: 0.2 %Kao-sung: 0.1 %Kao-sung: 0.1 %Pakistan: 0.1 %Pakistan: 0.1 %San Lorenzo: 0.2 %San Lorenzo: 0.2 %Seattle: 0.2 %Seattle: 0.2 %United States: 0.2 %United States: 0.2 %[]: 0.8 %[]: 0.8 %三亚: 0.1 %三亚: 0.1 %上海: 3.7 %上海: 3.7 %东莞: 0.2 %东莞: 0.2 %东营: 0.1 %东营: 0.1 %中央邦: 0.2 %中央邦: 0.2 %元朗新墟: 0.1 %元朗新墟: 0.1 %兰州: 0.3 %兰州: 0.3 %内江: 0.1 %内江: 0.1 %凉山: 0.1 %凉山: 0.1 %北京: 8.1 %北京: 8.1 %南京: 1.3 %南京: 1.3 %南充: 0.2 %南充: 0.2 %南宁: 0.5 %南宁: 0.5 %南阳: 0.1 %南阳: 0.1 %台北: 0.1 %台北: 0.1 %台州: 0.3 %台州: 0.3 %合肥: 0.1 %合肥: 0.1 %吉林: 2.8 %吉林: 2.8 %吉隆坡: 0.1 %吉隆坡: 0.1 %呼和浩特: 0.1 %呼和浩特: 0.1 %哈密: 0.1 %哈密: 0.1 %哥伦布: 0.2 %哥伦布: 0.2 %大同: 0.2 %大同: 0.2 %大连: 0.2 %大连: 0.2 %天津: 0.5 %天津: 0.5 %威海: 0.1 %威海: 0.1 %宣城: 0.1 %宣城: 0.1 %宿迁: 0.2 %宿迁: 0.2 %常州: 0.1 %常州: 0.1 %常德: 0.1 %常德: 0.1 %广州: 0.9 %广州: 0.9 %开封: 0.1 %开封: 0.1 %张家口: 2.3 %张家口: 2.3 %徐州: 0.1 %徐州: 0.1 %成都: 0.7 %成都: 0.7 %扬州: 0.2 %扬州: 0.2 %无锡: 0.3 %无锡: 0.3 %昆明: 1.1 %昆明: 1.1 %杭州: 0.8 %杭州: 0.8 %武汉: 0.9 %武汉: 0.9 %沈阳: 0.4 %沈阳: 0.4 %洛杉矶: 0.3 %洛杉矶: 0.3 %济南: 0.1 %济南: 0.1 %济宁: 0.2 %济宁: 0.2 %海口: 0.4 %海口: 0.4 %海得拉巴: 0.1 %海得拉巴: 0.1 %深圳: 1.1 %深圳: 1.1 %湘潭: 0.1 %湘潭: 0.1 %盐城: 0.2 %盐城: 0.2 %石家庄: 0.1 %石家庄: 0.1 %福州: 0.2 %福州: 0.2 %秋明: 0.1 %秋明: 0.1 %美国伊利诺斯芝加哥: 0.1 %美国伊利诺斯芝加哥: 0.1 %芒廷维尤: 33.0 %芒廷维尤: 33.0 %芝加哥: 0.5 %芝加哥: 0.5 %苏州: 0.1 %苏州: 0.1 %莫斯科: 1.2 %莫斯科: 1.2 %蚌埠: 0.1 %蚌埠: 0.1 %衡水: 0.2 %衡水: 0.2 %衡阳: 0.2 %衡阳: 0.2 %西宁: 16.4 %西宁: 16.4 %西安: 0.2 %西安: 0.2 %诺沃克: 0.2 %诺沃克: 0.2 %贵阳: 0.2 %贵阳: 0.2 %赣州: 0.2 %赣州: 0.2 %赤峰: 0.1 %赤峰: 0.1 %辽源: 0.1 %辽源: 0.1 %运城: 1.0 %运城: 1.0 %通化: 0.1 %通化: 0.1 %郑州: 0.5 %郑州: 0.5 %重庆: 0.4 %重庆: 0.4 %长春: 4.1 %长春: 4.1 %长沙: 0.9 %长沙: 0.9 %长治: 0.1 %长治: 0.1 %青岛: 0.3 %青岛: 0.3 %驻马店: 0.1 %驻马店: 0.1 %黄冈: 0.2 %黄冈: 0.2 %其他其他BengaluruCentral DistrictChinaIndiaKao-sungPakistanSan LorenzoSeattleUnited States[]三亚上海东莞东营中央邦元朗新墟兰州内江凉山北京南京南充南宁南阳台北台州合肥吉林吉隆坡呼和浩特哈密哥伦布大同大连天津威海宣城宿迁常州常德广州开封张家口徐州成都扬州无锡昆明杭州武汉沈阳洛杉矶济南济宁海口海得拉巴深圳湘潭盐城石家庄福州秋明美国伊利诺斯芝加哥芒廷维尤芝加哥苏州莫斯科蚌埠衡水衡阳西宁西安诺沃克贵阳赣州赤峰辽源运城通化郑州重庆长春长沙长治青岛驻马店黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1149) PDF downloads(97) Cited by(7)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2462]YesterdayPV[4905]TodayIP[230]TodayPV[514]Online[30]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return